Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce major adverse cardiovascular events in diabetics.
- The effects of GLP-1 RAs on cardiac health in diabetics treated with anthracyclines are under investigation.
- Potential impacts on cancer mortality among this population are also being explored.
- Overall mortality effects of GLP-1 RAs in the context of anthracycline treatment are a focus of this study.
Simplified